Pfizer and Johnson & Johnson have settled their legal battle over anticompetitive practices marketing their two immunology drugs, J&J’s blockbuster Remicade and Pfizer’s biosimilar Inflectra, according to a report from the American Journal of Managed Care’s Center for Biosimilars. While terms of the settlement were not disclosed, Pfizer will continue to market Inflectra. For the treatment of ulcerative colitis, Remicade remains advantaged over Inflectra, holding covered or better status for 59% of all insured lives under the pharmacy benefit and 91% under the medical benefit. Meanwhile, Inflectra is covered or better for 50% of lives under the pharmacy benefit and 90% under the medical benefit.
SOURCE: MMIT Analytics, as of 7/28/21